Table 1 Characteristics of cohort
From: Vitamin B12 measurements across neurodegenerative disorders
AD (n = 204) | DLB (n = 36) | FTD (n = 24) | MCI (n = 290) | MSA (n = 9) | PD (n = 130) | PSP (n = 20) | P-value* | |
|---|---|---|---|---|---|---|---|---|
Age at diagnosis, mean (sd) | 74.4 (9.7) | 73.4 (8.6) | 68.4 (8.6) | 70.4 (9.9) | 66.1 (3.6) | 68 (10.2) | 69.9 (6.3) | < 0.001** |
Age at time of B12, mean (sd) | 73.8 (9.7) | 73 (8.6) | 67.7 (8.5) | 69.8 (9.9) | 65.1 (3.8) | 68.4 (9.7) | 69 (6.1) | < 0.001** |
Female (%) | 118 (57.8) | 17 (47.2) | 11 (45.8) | 150 (51.7) | 3 (33.3) | 51 (39.2) | 9 (45) | 0.04 |
B12 level (pg/ml), mean (sd) | 465.1 (165.5) | 518.7 (180.4) | 542.9 (159.3) | 499.4 (180.7) | 549.8 (145.6) | 454.7 (168.4) | 539.1 (178.1) | 0.015** |
Patients with B12 < 250 pg/ml (%) | 13 (6.4) | 2 (5.6) | 0 | 18 (6.2) | 0 | 13 (10.0) | 1 (5.0) | 0.69 |
Medications (%) | ||||||||
Levodopa | 1 (0.5) | 20 (55.6) | 0 | 0 | 5 (55.6) | 116 (89.2) | 9 (45) | < 0.001 |
Multivitamin | 58 (28.4) | 6 (16.7) | 6 (25) | 85 (29.3) | 1 (11.1) | 23 (17.7) | 3 (15.0) | 0.10 |
Vitamin B12 | 16 (7.8) | 3 (8.3) | 2 (8.3) | 18 (6.2) | 0 | 2 (1.5) | 2 (10.0) | 0.13 |
Metformin | 11 (5.4) | 7 (19.4) | 1 (4.2) | 27 (9.3) | 0 | 4 (3.1) | 2 (10.0) | 0.02 |
PPII | 28 (13.7) | 8 (22.2) | 4 (16.7) | 54 (18.6) | 0 | 16 (12.3) | 5 (25.0) | 0.27 |